Pfizer Faces Legal Windfall and Tariff Shield in Eventful Week

Pfizer wins a major EU court case for €1.9B while its US tariff rate stays at 0% until 2029. The pharma giant faces a key shareholder vote on executive pay.

Two significant external developments are shaping the investment narrative for Pfizer this week, presenting a complex picture for the pharmaceutical giant. The company stands to gain from a major European court ruling while simultaneously being insulated from newly announced U.S. import tariffs.

A Shield Against New U.S. Tariffs

The U.S. administration has declared its intention to impose 100% tariffs on patented pharmaceuticals under Section 232 of the 1962 Trade Expansion Act. These duties are set to take effect for large corporations after a 120-day period. However, Pfizer is among the industry players largely protected from this measure. The company secured pricing agreements based on the "Most Favored Nation" principle with the U.S. Department of Health and Human Services, alongside production relocation deals with the Department of Commerce, back in 2025. As a result, Pfizer's effective tariff rate will remain at zero percent until January 20, 2029.

A total of sixteen major pharmaceutical firms, including AbbVie, Eli Lilly, Novo Nordisk, and Johnson & Johnson, have entered into similar arrangements. For now, generic drugs and biosimilars are exempt from the new tariffs, with a reassessment scheduled in one year.

A Major Legal Victory in Europe

In a separate but substantial development, a Belgian court has ordered Poland and Romania to pay Pfizer a combined sum of €1.9 billion. The ruling stems from the countries' failure to fully accept deliveries of COVID-19 vaccines they ordered during the pandemic, effectively breaching their contracts. The court dismissed the defendants' arguments, finding that neither declining infection rates nor the impact of the war in Ukraine on Poland constituted valid grounds for contract termination.

Poland is liable for approximately €1.3 billion, with Romania owing around €600 million. Although this is a first-instance judgment, it is immediately enforceable. Both nations have announced plans to appeal. Romanian officials noted that the demanded amount could finance the construction of a major regional hospital, suggesting the legal dispute may continue for years. A related case against Hungary, involving roughly €60 million, is scheduled for April 16.

Shareholder Meeting and Financial Outlook

Pfizer's share price has recovered by about 24% over the past twelve months, though it remains down approximately 18% on a three-year basis. The company will hold its virtual Annual Meeting of Shareholders on April 23. A key agenda item is the advisory vote on executive compensation, a topic that has recently become contentious. While such votes averaged 93.5% approval from 2015 through 2024, support plummeted to just 54.7% in 2025.

Looking ahead, Pfizer is scheduled to report quarterly earnings on May 5, 2026. The company anticipates net savings of roughly $5.7 billion from its ongoing cost-reduction program by the end of 2026. An additional $1.5 billion in savings from production optimization is expected by 2027.